Cold Atmospheric Plasma Versus Cisplatin Against Oral Squamous Cell Carcinoma: A Mitochondrial Targeting Study

Mona Afrasiabi, Ghazaleh Tahmasebi, Esmaeil Eslami, Enayatollah Seydi, and Jalal Pourahmad

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Atomic/Molecular Physics, Faculty of Physics, Iran University of Science and Technology, Tehran, Iran
Department of Occupational Health and Safety Engineering, School of Health, Alborz University of Medical Sciences, Karaj, Iran
Research Center for Health, Safety and Environment, Alborz University of Medical Sciences, Karaj, Iran

Corresponding author: Department of Occupational Health and Safety Engineering, School of Health, Alborz University of Medical Sciences, Karaj, Iran; Research Center for Health, Safety and Environment, Alborz University of Medical Sciences, Karaj, Iran. Email: enayat.seydi@yahoo.com

Abstract

Plasma therapy and the study of the effects of cold atmospheric plasma (CAP) on tissues and living cells have been considered by scientific researchers in recent years. CAP is used in the treatment of cancer, but its anti-cancer mechanism has not been fully studied. Therefore, we studied the toxicity effect of CAP by using argon as feed gas and the synergistic effects of CAP with cisplatin on tumor cells and mitochondria isolated from tumor legions of the rat model of oral squamous cell carcinoma (OSCC). For this reason, we determined the possible toxic alterations of CAP on mitochondrial upstream events and activation of caspase-3 as the key major downstream event of apoptosis. Also, the effects of cisplatin (10 µM) as a positive control and its synergic effects with CAP (IC50 concentration) were investigated. The results showed that CAP reduced mitochondrial dysfunction by reduction in succinate dehydrogenase (SDH) activity. Also, CAP in concentrations of 1200, 2400, and 4800 a.u. has been able to increase the level of reactive oxygen species (ROS), mitochondrial swelling, damage to the mitochondrial membrane, cytochrome c release, and activation of the final mediator of apoptosis (caspase-3) only in the OSCC group. CAP at 4800 a.u. concentration had similar effects to cisplatin (10 µM). Synergistic effects between CAP (2400 a.u) and cisplatin (10 µM) have also been reported. Based on all results, CAP showed positive and promising results on mitochondrial upstream parameters leading to activation of caspase-3, the final mediator of apoptosis only on OSCC cells and mitochondria without any significant effect on normal cells and mitochondria.

Keywords: Squamous Cell Carcinoma of Head and Neck, Cold Plasma, Mitochondria, Reactive Oxygen Species, Apoptosis

1. Background

In recent years, various technologies have been used in various branches of medicine, each of which has its advantages and disadvantages. But it should be borne in mind that today the use of optimal plasma in various fields, especially medicine has made significant progress (1-3). Humans have naturally been exposed to plasma. Plasma is a type of ionized gas, and because there is always a small amount of ionization in each gas, not every ionized gas can be called plasma (4). The anti-cancer effects of cold atmospheric plasma (CAP) on various cells have so far been investigated in both in vitro and in vivo studies (5-7). CAP has potential effects on cancer cells and low cytotoxicity on normal cells, so it is known as a useful tool in the treatment of cancer. According to studies, the incidence of cancer is increasing (8-10). The selective effect on cancer cells and the lack of side effects on normal cells are features of an ideal anti-cancer therapy (11).

There is a positive correlation between a rise in the level of free radicals and the anti-cancer effects of CAP. CAP generates a lot of reactive oxygen species (ROS) that cross from the nuclear membrane and cause serious damage to DNA in cancerous cells but it has no thermal effects leading to a biological response. CAP has been shown to induce apoptotic signaling in cancer cells via the mitochondrial pathway. CAP-induced ROS causes a rise in mitochondrial membrane permeability and the release of cytochrome c (as a main pro-apoptotic protein), leading to activation of apoptosis signaling. Thus, CAP can kill cancer cells through ROS (3, 6, 12, 13). Today, the prevalence of cancer is increasing. Worldwide, oral squamous cell carcinoma (OSCC) is known...
as one of the most important malignancies that often occurs in the head and neck. It is also known as one of the most important types of oral cancer and tobacco and alcohol are the most important risk factors (14-16). Cisplatin is an anticancer agent commonly present in chemotherapeutic regimens used for the treatment of OSCC. Different methods for the treatment of OSCC can be problematic due to side effects on non-specific cells. So there is a major need to develop new anticancer strategies for the treatment of OSCC with a more selective cytotoxic effect on this tumor cells and preferably no toxicity on other normal body cells.

Research has shown that various compounds can induce apoptosis and increase the level of ROS in OSCC cells, and can help treat this cancer (17-20). Furthermore, cancer cells are vulnerable to free radicals (ROS) and oxidative stress. ROS can induce apoptotic signaling. So, factors that can increase the generation of ROS and induce apoptosis in cancer cells have been considered. Mitochondria are vital organelles involved in ROS generation and cell death. In recent years, mitochondria have been the focus of cancer research due to their unique properties. Various studies have shown that different compounds with impaired mitochondrial function can increase the level of ROS and apoptosis in cancer cells.

2. Objectives

This research was planned to evaluate the selective toxicity of CAP on OSCC cells and mitochondria with the possible synergistic effects of cisplatin.

3. Methods

3.1. Chemical

Rhodamine 123 (Rh 123), 2,7-dichlorofluorescein diacetate (DCHF-DA), and caspase-3 assay kit were purchased from Sigma Chemical Co (St. Louis, MO). Cytochrome c assay kit was purchased from R&D Systems, Inc. (Minneapolis, MN). Also, other chemicals were of the highest commercial grade available.

3.2. Cold Atmospheric Plasma (CAP) Treatment

The characteristics of the CAP device and its treatment scheme are described in our previous study (Figure 1A and B, Table 1) (21). The device made at the Iran University of Science and Technology was a DBD-Like plasma jet to produce CAPP. In this research, the glass flow meter model KT800-6 with the ability to measure 1000 - 100 liters per hour with an accuracy of 40 liters per hour, has been used to control and measure the flow rate of gas. To form plasma, the applied voltage must be higher than the breakdown voltage. To use plasma to treat isolated mitochondria, it was necessary to test the power supply at different voltages and frequencies. In plasma jets that use noble gases such as helium and argon, the voltage and frequency are about kV and kHz, respectively, which are used in the treatment of cancer and the effect on DNA. In this study, the feeding gas was 99.999% pure Argon (Ar). Also, the gas pressure used in the experiments was 600 NL/h, approximately equal to 10 liters per minute. The time durations for plasma treatment were 30, 60, and 120 sec (21, 22). Our time for mitochondrial OSCC treatment was 30, 60, and 120 sec. Also, the plasma dose was calculated based on D ~ Q * V * T (Table 1). The characteristics of the CAP are shown in Table 1. CAP concentrations (1200, 2400, and 4800 a.u.) were used based on our previous study.

3.3. Animals

In this study, normal rats and rats with OSCC were obtained from Iran Cancer Institute. Animal care conditions (temperature 20 - 25°C; light/dark cycle 12:12 h; humidity 50 - 60%) and experiments have been performed according to the ethical standards and protocols of Shahid Beheshti University of Medical Sciences in Tehran, Iran, and our study was approved by the research ethics committee of Shahid Beheshti University of Medical Sciences with the approval code (IR.SBMU.PHARMACY.REC.1397.234).

3.4. Mitochondria Isolation

After the separation of OSCC and normal tissues, DMEM culture media was used for suspension. In the next step, the samples obtained from both groups were homogenized. Two centrifugation steps were used to isolate mitochondria. The first step, centrifugation at 500 × g for 15 minutes at 4°C and second step, centrifugation at 5000 × g for 15 minutes at 4°C (23). MTT test and cytochrome c oxidase (complex IV) assay kit were used to evaluate the mitochondrial function and the mitochondrial membrane integrity, respectively. Finally, tests were performed on mitochondria.

3.5. Evaluation of Succinate Dehydrogenase (SDH) Activity

Initially, Tris buffer was used to suspend isolated mitochondria from both groups. Then, the mitochondria obtained from both groups were exposed to CAP (1200, 2400 and 4800 a.u), cisplatin (10 μM); as a positive control; and CAP (2400 a.u) plus cisplatin (10 μM), and then incubated for 1 hour at 37°C. Then, succinate dehydrogenase (SDH) activity was evaluated after adding MTT dye (0.4%) and
Table 1. Technical Parameters of the Cold Atmospheric Plasma (CAP) Settings Applied to Mitochondria

| Cold Atmospheric Plasma (CAP) Parameters | Values                                                                 |
|-----------------------------------------|------------------------------------------------------------------------|
| Voltage (kV)                            | 4                                                                     |
| Frequency (kHz)                         | 40                                                                   |
| Time (s)                                | 30, 60, 120                                                           |
| Plasma dose                             | D is the entire “plasma dosage” applied to mitochondria; Q is the flow rate of the feeding gas, V is the output voltage and T is the treatment time |

3.6. Evaluation of ROS Level

DCHF-DA reagent was used to evaluate the level of ROS. Briefly, isolated mitochondria were suspended in the respiratory assay buffer and then exposed to different doses (1200, 2400 and 4800 a.u) of CAP, cisplatin (10 µM), and CAP (2400 a.u) plus cisplatin (10 µM). Then, a DCHF-DA reagent (10 µM) was added to the mitochondrial suspension and the incubation process was performed for 1 hour at 37°C. Next, the level of ROS was assessed using a fluorescence spectrophotometer (EX = 488 nm and EM = 527 nm) (21).

3.7. Evaluation of Mitochondrial Swelling

Initially, isolated mitochondria from both groups were suspended in mitochondrial swelling assay buffer (sucrose (70 mM), mannitol (230 mM), HEPES (3 mM), Tris-phosphates (2 mM), succinate (5 mM), and rotenone (1 M)). Then, the mitochondria obtained from both groups were exposed to different doses (1200, 2400 and 4800 a.u) of CAP, cisplatin (10 µM), and CAP (2400 a.u) plus cisplatin (10 µM), and then incubated for 1 hour at 37°C. Then, mitochondrial swelling was evaluated at an absorbance of 540 nm (ELISA reader).

3.8. Evaluation of MMP Collapse

Rh 123 reagent was used to evaluate the MMP collapse. Briefly, isolated mitochondria were suspended in the MMP assay buffer and then exposed to different doses (1200, 2400 and 4800 a.u) of CAP, cisplatin (10 µM) and CAP (2400 a.u) plus cisplatin (10 µM). Then, Rh 123 reagent (10 µM) was added to the mitochondrial suspension and the incubation process was performed for 1 hour at 37°C. Next, the MMP collapse was assessed using a fluorescence spectrophotometer (EX = 490 nm and EM = 535 nm) (26, 27).
3.9. Evaluation of Cytochrome C Release

The Quantikine Rat/Mouse Cytochrome c Immunoassay kit (R and D Systems, Inc., Minneapolis, MN, USA) was used for the determination of cytochrome c release.

3.10. Cell Isolation

Cell isolation was performed based on our previous study. First, the tissue samples were immersed in 70% ethanol solution for 20 s and then washed several times with PBS. In the next step, the samples were transferred to a DMEM culture medium. Tissue culture dishes were used to seed of small tissue pieces. Then, the primary cell cultures were incubated for 2 - 3 weeks to achieve 70% - 80% confluence at 37°C with CO2 (5%) (28, 29). In the following, the culture medium was changed every 3 to 4 days. Finally, 1 × 10⁴ cells/mL were used to evaluate the activity of caspase-3.

3.11. Evaluation of Caspase-3 Activity

In this study, the Sigma Caspase-3 assay kit (Sigma-Aldrich) was used to investigate the relationship between exposure to CAP at different doses (1200, 2400 and 4800 a.u) of CAP; cisplatin (10 µM); as a positive control; and CAP (2400 a.u) plus cisplatin (10 µM) on activation of caspase-3 in both groups. The concentration of p-nitroaniline released at the absorbance wavelength of 405 nm is considered an indicator of caspase-3 activation (30).

3.12. Statistical Analysis

Statics are presented as mean ± SD. All statistical tests were carry out using GraphPad Prism (GraphPad Prism software, version 6). Statistical significance set at P < 0.05. Data were analyzed using one-way analysis of variance (ANOVA) followed by the Tukey’s test.

4. Results

4.1. CAP and Mitochondrial SDH Activity

In the OSCC mitochondria, the results showed that CAP was able to reduce SDH activity at doses of 1200, 2400 and 4800 a.u. However, CAP at these doses had no effect on SDH activity in normal mitochondria (Figure 2A). Also, cisplatin (10 µM) as a positive control reduced the activity of SDH. CAP at 4800 a.u dose had similar effects to cisplatin (10 µM) on activation of caspase-3 in both groups. The concentration of p-nitroaniline released at the absorbance wavelength of 405 nm is considered an indicator of caspase-3 activation (30).

4.2. CAP and Mitochondrial ROS Level

As shown in Figure 2B, exposure of OSCC mitochondria to CAP has been associated with an increase in ROS generation. A significant increase in the level of ROS in the OSCC mitochondria was observed at all doses (1200, 2400 and 4800 a.u). In normal mitochondria, this effect due to CAP exposure has not been reported (Figure 2B). The results showed that CAP at the highest concentration had similar effects to cisplatin (10 µM). Also, synergistic effects between CAP (2400 a.u) plus cisplatin (10 µM) have been reported (Figure 2B).

4.3. CAP and Mitochondrial Swelling

Mitochondrial swelling can be considered as one of the events in signaling apoptosis. Results indicated that there is a positive relationship between the exposure of OSCC mitochondria to CAP (1200, 2400 and 4800 a.u) and mitochondrial swelling (Figure 3A). This mitochondrial dysfunction was not observed in the normal group. Furthermore, the results showed that there was no significant relationship between CAP (4800 a.u) and cisplatin (10 µM), and plasma similar to cisplatin could cause mitochondrial swelling. Compared to the other groups, the highest mitochondrial swelling was observed in the CAP (2400 a.u) plus cisplatin (10 µM) group, which could indicate synergistic effects (Figure 3A).

4.4. CAP and MMP Collapse

As shown in Figure 3B, exposure of OSCC mitochondria to CAP has been associated with an increase in the MMP collapse. A significant increase in the MMP collapse in the OSCC mitochondria was observed at all doses (1200, 2400 and 4800 a.u). In normal mitochondria, this effect due to CAP exposure has not been reported (Figure 3B). Cisplatin at a concentration of 10 µM caused a collapse in the MMP. CAP at 4800 a.u dose had similar effects to cisplatin (10 µM) on MMP collapse. Furthermore, exposure to CAP (2400 a.u) plus cisplatin (10 µM) significantly caused a collapse in the MMP compared to other groups (Figure 3B).

4.5. CAP and Cytochrome C Release

In apoptosis, the release of cytochrome c is an important event. In the OSCC mitochondria, the results showed that CAP was able to release cytochrome c at doses of 1200, 2400 and 4800 a.u. However, CAP at these doses had no effect on cytochrome c release in normal mitochondria (Figure 4A). Also, cisplatin (10 µM) similarly caused cytochrome c release from the OSCC mitochondria, and no significant difference was observed between the two groups. Also, synergistic effects
Figure 2. A, Cold atmospheric plasma (CAP) and succinate dehydrogenase (SDH) activity in normal and oral squamous cell carcinoma (OSCC) mitochondria [results displayed as mean ± SD (n = 3); *** P < 0.001 compared with the control group; ### P < 0.001 compared with the control group and CAP (1200 a.u and 2400 a.u); $$$ P < 0.01 compared with the control and CAP (1200 a.u, 2400 a.u and 4800 a.u) group; $ P < 0.01 compared with the cisplatin (10 µM) group]; B, CAP and ROS level in normal and OSCC mitochondria [results displayed as mean ± SD (n = 3); ** P < 0.01 *** P < 0.001 compared with the control group; ### P < 0.001 compared with the control and CAP (1200 a.u) group; ## P < 0.01 compared with the CAP (2400 a.u) group; $$$ P < 0.01 compared with the control and CAP (1200 a.u, 2400 a.u and 4800 a.u) group; $ P < 0.01 compared with the cisplatin (10 µM) group].

Figure 3. A, Cold atmospheric plasma (CAP) and mitochondrial swelling in normal and oral squamous cell carcinoma (OSCC) mitochondria [results displayed as mean ± SD (n = 3); *** P < 0.001 compared with the control group; ### P < 0.001 compared with the control and CAP (1200 a.u) group; ## P < 0.01 compared with the CAP (2400 a.u) group; $$$ P < 0.01 compared with the control and CAP (1200 a.u, 2400 a.u and 4800 a.u) group; $ P < 0.01 compared with the cisplatin (10 µM) group]; B, CAP and MMP collapse in normal and OSCC mitochondria [results displayed as mean ± SD (n = 3); ** P < 0.01 *** P < 0.001 compared with the control group; ### P < 0.001 compared with the control and CAP (1200 a.u and 2400 a.u) group; $$$ P < 0.001 compared with the control, CAP (1200 a.u, 2400 a.u and 4800 a.u) and cisplatin (10 µM) group].
between CAP (2400 a.u) plus cisplatin (10 µM) have been reported (Figure 4A).

### 4.6. CAP and Caspase-3 Activity

Results indicated that there is a positive relationship between the exposure of OSCC group to CAP (1200, 2400 and 4800 a.u) and caspase-3 activity (Figure 4B). P-nitroaniline concentration levels are used to evaluate caspase-3 activity. This event was not observed in the normal group. Additionally, results indicated that there was no significant difference between CAP (4800 a.u) and cisplatin (10 µM), and plasma similar to cisplatin could cause caspase-3 activation. Compared to the other groups, the highest caspase-3 activity was observed in the CAP (2400 a.u) plus cisplatin (10 µM) group (Figure 4B).

### 5. Discussion

This in vitro research was designed to study the apoptotic effects of CAP and cisplatin treatment on OSCC mitochondria and cells. Common approaches to the treatment of OSCC are controversial as one of the most important types of head and neck cancer (31, 32). In past years, the use of CAP in the treatment of different malignancies has attracted the attention of researchers. Cancer treatment based on traditional methods is costly and time-consuming. It can also damage normal cells. In the treatment of cancer, the use of cold plasma is cheaper and the damage to normal cells is less (33, 34). Mitochondrial SDH activity after the application of the CAP was measured using an MTT test. It was proven that the CAP can decrease the activity only of the OSCC mitochondria.

It is well known that mitochondria are involved in cell death and the generation of ROS. It has been shown that plasma anticancer activity is mediated by mitochondrial dysfunction. In addition, mitochondrial dysfunction is associated with the induction of apoptotic signaling and a rise in ROS levels (3, 35, 36). Studies have shown that the generation of ROS is effective in the treatment of cancer (37, 38). One of the mechanisms by which cold plasma induces apoptosis in cancer cells is an increase in the level of ROS in these cells (12, 39). Compared to normal cells, it should be noted that cancer cells are more sensitive to endogenous free radicals (ROS) (40). CAP treatment resulted in an increase in ROS generation in the OSCC mitochondria. It can be concluded that OSCC mitochondria are more sensitive to CAP treatment than normal mitochondria. Our results are similar to previous studies (12, 21, 39).

The collapse in the MMP and mitochondrial swelling are the hallmarks of the permeability of mitochondrial inner membrane (MIM) to various compounds. It has been shown that ROS are effective in mitochondrial membrane permeability. In addition, cytochrome c release and cell death can be affected by ROS (41-43). In this research, we found that in vitro CAP treatment increased the MMP collapse. Our results also showed that CAP resulted in mitochondrial swelling. CAP treatment had no effect on the normal mitochondria at the exposure time tested. The results of this study suggest that plasma is likely to disrupt the OSCC mitochondrial membrane potential through ROS. Eventually, it causes collapse of the MMP and mitochondrial swelling.

Subsequently, treatment of OSCC mitochondria to CAP was associated with cytochrome c release. ROS are involved in the release of cytochrome c through its effect on mitochondrial membrane permeability. This result is also in agreement with our previous study (21). Results indicated that there was a significant increase in caspases-3 activity following CAP treatment in OSCC cells. Caspase-3 is one of the important factors that play a role in cell death (44, 45). In cancer cells, the concentration of ROS plays an important role in the mechanism of caspase-mediated apoptosis (46). Based on these results, it can be suggested that CAP-induced ROS are involved in the activation of caspase-3 followed by cell death.

### 5.1. Conclusions

The results of the study suggest that CAP can increase the level of ROS by targeting cancerous mitochondria. Then, the permeability of the OSCC mitochondrial membrane is affected by ROS, resulting in collapse of the MMP and mitochondrial swelling. Subsequently, mitochondrial swelling was associated with the release of cytochrome c as a pro-apoptotic proteins and the activation of caspase-3. Considering the fact that combination of CAP and cisplatin significantly increased all toxicity parameters, our results suggest CAP as a promising therapeutic complementary candidate against OSCC and suggest the process for further investigation.

### Footnotes

**Authors’ Contribution:** Mona Afrasiabi contributed to this research in carrying out the experiments and performing statistical analysis as the thesis student. Enayatollah Seydi contributed to this research in analyzing the data and writing the paper. Ghazaleh Tahmasebi, Esmaeil Esfandi contributed in this research in carrying out some experiments. Jalal Pourahmad contributed to this research in formulating the research question(s), designing the
A (Cytochrome c release)

B (Caspase-3 activity)

Figure 4. A, Cold atmospheric plasma (CAP) and cytochrome c release (1200, 2400, and 4800 a.u) in normal and oral squamous cell carcinoma (OSCC) mitochondria [results displayed as mean ± SD (n = 3); **P < 0.01 compared with the control group; ***P < 0.001 compared with the control and CAP (1200 a.u and 2400 a.u) group; $$$$P < 0.001 compared with the control, CAP (1200 a.u, 2400 a.u and 4800 a.u) and cisplatin (10 µM) group]. B, CAP and caspase-3 activity (1200, 2400, and 4800 a.u) in normal and OSCC mitochondria. Results displayed as mean ± SD (n = 3); **P < 0.01 ***P < 0.001 compared with the control group; ###P < 0.001 compared with the control and CAP (1200 a.u and 2400 a.u) group; $$$$P < 0.001 compared with the control, CAP (1200 a.u, 2400 a.u and 4800 a.u) and cisplatin (10 µM) group].

study, carrying it out as thesis supervisor, analyzing the data, and writing paper.

Conflict of Interests: The authors declare no conflict of interest. Jalal Pourahmad is on the editorial board of the journal and was not involved in the review process of the current manuscript.

Ethical Approval: IR.SBMU.PHARMACY.REC.1397.234.

Funding/Support: This study was supported in part by grant 14964 from the Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Informed Consent: Uploaded in the supplementary files during the submission.

References

1. Boeckmann L, Schafer M, Bernhardt T, Semmler ML, Jung O, Ojak G, et al. Cold Atmospheric Pressure Plasma in Wound Healing and Cancer Treatment. Appl Sci. 2020;10(19):6898. [PubMed Central ID: PMC4738260]. https://doi.org/10.3390/app10196898.

2. Jalili A, Irani S, Mirtakhraie R. Combination of cold atmospheric plasma and iron nanoparticles in breast cancer: gene expression and apoptosis study. Onco Targets Ther. 2016;9:5917. [PubMed ID: 27292400]. [PubMed Central ID: PMCS047223]. https://doi.org/10.2147/OTT.S95644.

3. Kim SJ, Chung TH. Cold atmospheric plasma jet-generated RONS and their selective effects on normal and carcinoma cells. Sci Rep. 2016;6:20332. [PubMed ID: 26838106]. [PubMed Central ID: PMC4738260]. https://doi.org/10.1038/srep20332.

4. National Research Council. Plasma Processing of Materials: Scientific Opportunities and Technological Challenges. Washington, USA: The National Academies Press; 1991. https://doi.org/10.17226/1875.

5. Gay-Mimbrera J, Garcia MC, Isla-Tejera B, Rodero-Serrano A, Garcia-Nieto AV, Ruano J. Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer. Adv Ther. 2016;33(6):894-909. [PubMed ID: 27432848]. [PubMed Central ID: PMC4929055]. https://doi.org/10.1007/s12325-016-0338-1.

6. Saadati F, Mahdikia H, Abbaszadeh HA, Abdollahifar MA, Khoramgah MS, Shokri R. Comparison of Direct and Indirect cold atmospheric-pressure plasma methods in the B16F10 melanoma cancer cells treatment. Sci Rep. 2018;8(1):7659. [PubMed ID: 29769707]. [PubMed Central ID: PMC595919]. https://doi.org/10.1038/s41598-018-25990-9.

7. Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Ishikawa K, et al. Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo. PLoS One. 2018;13(8):e0214106. [PubMed ID: 24367486]. [PubMed Central ID: PMC3867316]. https://doi.org/10.1371/journal.pone.00214106.

8. Saad El Din K, Loree JM, Sayre EC, Gill S, Brown CJ, Dau H, et al. Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. BMC Cancer. 2020;20(1):288. [PubMed ID: 32252672]. [PubMed Central ID: PMC713705]. https://doi.org/10.1186/s12888-020-06766-9.
via p38/MAPK Mechanism in U87 Malignant Glioblastoma. 
Cancers (Basel). 2020;12(1):245. [PubMed ID: 3963881]. [PubMed Central ID: PMC7016658]. https://doi.org/10.3390/cancers12010245.

38. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods. 2002;265(1-2):49-72. [PubMed ID: 12072178]. https://doi.org/10.1016/s0022-1759(02)00070-4.

39. Dezest M, Chavatte L, Bourdems M, Quinton D, Camus M, Garrigues L, et al. Mechanistic insights into the impact of Cold Atmospheric Pressure Plasma on human epithelial cell lines. Sci Rep. 2017;7:4163. [PubMed ID: 28120925]. [PubMed Central ID: PMC5264585]. https://doi.org/10.1038/srep4163.

40. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7(2):97-110. [PubMed ID: 15158766]. https://doi.org/10.1016/j.drup.2004.01.004.

41. Barkhade T, Mahapatra SK, Banerjee I. Study of mitochondrial swelling, membrane fluidity and ROS production induced by nano-TiO2 and prevented by Fe incorporation. Toxicol Res (Camb). 2009;5(3):71-22. [PubMed ID: 19583348]. [PubMed Central ID: PMC6744460]. https://doi.org/10.1093/toxres/5x0043c.

42. Peng TI, Jou MJ. Mitochondrial swelling and generation of reactive oxygen species induced by photoradiation are heterogeneously distributed. Ann N Y Acad Sci. 2004;1011:112-22. [PubMed ID: 15126289]. https://doi.org/10.1007/978-3-662-41088-2_12.

43. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-90. [PubMed ID: 15178689]. https://doi.org/10.1074/jbc.M402999200.

44. Ke H, Wang X, Zhou Z, Ai W, Wu Z, Zhang Y. Effect of weimaining on apoptosis and Caspase-3 expression in a breast cancer mouse model. J Ethnopharmacol. 2021;264:113363. [PubMed ID: 32916234]. https://doi.org/10.1016/j.jep.2020.113363.

45. Nichani K, Li J, Suzuki M, Houston JP. Evaluation of Caspase-3 Activity During Apoptosis with Fluorescence Lifetime-Based Cytometry Measurements and Phasor Analyses. Cytometry A. 2020;97(12):265-75. [PubMed ID: 32790129]. [PubMed Central ID: PMC7738394]. https://doi.org/10.1002/cyto.a.24207.

46. Min Joh H, Ja Kim S, Chung TH, Leem SH. Reactive oxygen species-related plasma effects on the apoptosis of human bladder cancer cells in atmospheric pressure pulsed plasma jets. Appl Phys Lett. 2012;101(5):53701. https://doi.org/10.1063/1.4742742.